Medication info
Amozartan XQ Tablets 5/50/20/10 mg

Amozartan XQ Tablets 5/50/20/10 mg

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletEzetimibe›10mg / 1 tabletAmlodipine Besylate›6.94mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP × 3]
Approval status
Active

MFDS item code 202007692 · Approved 2020.11.09 · Insurance code 643508350

Summary

Main use
Treatment of hypertension and dyslipidemia (hypercholesterolemia, etc.)
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and the rosuvastatin/ezetimibe combination. The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Swallow the tablet whole without chewing, dividing, or crushing it. ○ Amlodipine/losartan combination The recommended dose of the amlodipine/losartan combination is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or losartan). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into account baseline blood pressure, target blood pressure, and the anticipated likelihood of achieving the treatment goal with the combination compared with a single agent. The usual dose is amlodipine/losartan 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ∘ Patients with renal impairment: Dose adjustment is not required in patients with mild renal impairment; however, use of the amlodipine/losartan combination is not recommended in patients with moderate renal impairment. ∘ Patients with reduced intravascular volume: Use of the amlodipine/losartan combination is not recommended in a small number of patients with reduced intravascular volume (e.g., patients receiving high-dose diuretics). (See section 1, Warnings, under Precautions for Use.) ∘ Patients with hepatic impairment: Use of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduced dose of losartan (e.g., 25 mg once daily). ∘ Older adults: In older adults aged 75 years or over, an initial losartan dose of 25 mg once daily is recommended; therefore, use of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin/ezetimibe combination The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue to follow a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response to treatment. Primary hypercholesterolemia The dosage range of the rosuvastatin/ezetimibe combination is 5/10 mg to 20/10 mg once daily. The recommended initial dose is 5/10 mg once daily. The dose may be adjusted for patients who require a greater reduction in LDL cholesterol. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of at least 4 weeks and adjust the dose accordingly; the dose may be increased to a maximum of 20/10 mg once daily. Patients taking the amlodipine/losartan combination together with the rosuvastatin/ezetimibe combination may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia (hypercholesterolemia, etc.)

  • Essential hypertension
  • stage 2 hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
  • LDL-cholesterol
  • Apo B protein
  • triglycerides
  • and increased non-HDL-cholesterol
View approved original text

This medication is used for patients with both hypertension and dyslipidemia who require additional blood pressure and lipid control, particularly those taking an amlodipine/losartan combination and a rosuvastatin/ezetimibe combination. The amlodipine/losartan combination is indicated for patients with essential hypertension whose blood pressure is not controlled by monotherapy or for those with stage 2 hypertension requiring initial treatment. The rosuvastatin/ezetimibe combination effectively lowers blood cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia and is used alongside dietary changes to reduce the risk of atherosclerotic vascular diseases. This medication helps improve the risk of cardiovascular diseases by systematically managing blood pressure and lipid levels.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and the rosuvastatin/ezetimibe combination. The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Swallow the tablet whole without chewing, dividing, or crushing it. ○ Amlodipine/losartan combination The recommended dose of the amlodipine/losartan combination is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or losartan). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into account baseline blood pressure, target blood pressure, and the anticipated likelihood of achieving the treatment goal with the combination compared with a single agent. The usual dose is amlodipine/losartan 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ∘ Patients with renal impairment: Dose adjustment is not required in patients with mild renal impairment; however, use of the amlodipine/losartan combination is not recommended in patients with moderate renal impairment. ∘ Patients with reduced intravascular volume: Use of the amlodipine/losartan combination is not recommended in a small number of patients with reduced intravascular volume (e.g., patients receiving high-dose diuretics). (See section 1, Warnings, under Precautions for Use.) ∘ Patients with hepatic impairment: Use of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduced dose of losartan (e.g., 25 mg once daily). ∘ Older adults: In older adults aged 75 years or over, an initial losartan dose of 25 mg once daily is recommended; therefore, use of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin/ezetimibe combination The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue to follow a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response to treatment. Primary hypercholesterolemia The dosage range of the rosuvastatin/ezetimibe combination is 5/10 mg to 20/10 mg once daily. The recommended initial dose is 5/10 mg once daily. The dose may be adjusted for patients who require a greater reduction in LDL cholesterol. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of at least 4 weeks and adjust the dose accordingly; the dose may be increased to a maximum of 20/10 mg once daily. Patients taking the amlodipine/losartan combination together with the rosuvastatin/ezetimibe combination may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to the fetus if administered to pregnant women, so it should be discontinued immediately if pregnancy is confirmed. Blood pressure may drop sharply upon initial administration in patients with low blood volume, so in such cases, normalization of blood volume should occur before use. There is a risk of serious muscle problems, so if symptoms such as muscle pain or weakness occur, consultation with a doctor is necessary. This medication should not be used by individuals allergic to its components or those with specific liver or kidney diseases. Special precautions are necessary for the elderly, patients with impaired kidney function, or those with very low blood pressure when using this medication. This medication may affect liver and kidney function, so regular blood tests and liver function tests should be performed during treatment. To reduce the risk of muscle-related side effects, muscle test values should be monitored, and if abnormalities are found, drug use should be discontinued or adjusted. Drug interactions may occur when taken with other medications, so patients must inform their doctor or pharmacist of any other medications being taken. Care should be taken when driving or operating machinery due to potential dizziness. This medication contains lactose, so it should not be used by individuals with lactose intolerance.

Side effects

Craniosynostosis, anuria, hypotension, renal failure, elevated ALT, elevated AST, dermatitis, orthostatic dizziness, ventricular syncope, rhabdomyolysis, pancreatic carcinoma, facial edema, altered sensation, drug intolerance, colonic polyps, irritable bowel syndrome, esophagitis, dizziness, drowsiness, neurodegenerative disorders, migraine, diabetes, glucose tolerance disorder, depression, bronchitis, rhinitis, cystitis, onychomycosis, soft tissue inflammation, hepatic steatosis, liver dysfunction, hepatotoxicity, acute hepatitis, toxic hepatitis, increased gamma-glutamyl transferase, increased blood cholesterol, increased serum alkaline phosphatase, irregular heartbeat, osteoarthritis, osteoporosis, musculoskeletal stiffness, musculoskeletal discomfort, muscle weakness, diaphoresis, skin burning sensation, skin disorders, alopecia, oropharyngeal pain, nasal congestion, respiratory distress, pelvic pain, breast cysts, eyelid drooping, diabetic retinopathy, ear discomfort, renal dysfunction, benign esophageal neoplasm, flushing, fatigue, edema, palpitations, vertigo, headache, somnolence, abdominal pain, nausea, weakness, lethargy, pain, weight gain, weight loss, hypotension, vasculitis, tension increase, sensory reduction, paresthesia, peripheral neuropathy, syncope, taste alteration, tremor, erectile dysfunction, gynecomastia, changes in bowel habits, dry mouth, dyspepsia, gastritis, gingival hypertrophy, pancreatitis, vomiting, hyperglycemia, arthralgia, low back pain, muscle cramps, myalgia, leukopenia, thrombocytopenia, insomnia, mood changes, cough, dyspnea, rhinitis, hair loss, increased perspiration, purpura, skin discoloration, urticaria, toxic epidermal necrolysis, tinnitus, visual disturbances, increased urinary frequency, urinary dysfunction, nocturia, hepatitis, jaundice, elevated liver enzyme levels, vascular edema, vasculitis, anaphylactic-like syndrome, abnormal liver function, intestinal vascular edema, malaise, anemia, thrombocytopenia, myalgia, weakness, elevated creatine kinase, increased serum myoglobin, increased urinary myoglobin, taste alteration, dry cough, erythema, hyperkalemia, hyponatremia, elevated ALT, elevated AST, increased BUN, elevated serum creatinine, syncope, loss of consciousness, acute hepatitis, fulminant hepatitis, renal failure, ventricular extrasystole, atrial fibrillation, hypoglycemia, weakness, hunger, diaphoresis, tremors, decreased concentration, convulsions, altered consciousness, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myopathy, myositis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, anaphylaxis, urticaria, rash, vascular edema, erythema multiforme, arthralgia, elevated creatine phosphokinase, myopathy, rhabdomyolysis, elevated liver amino transferase levels, hepatitis, abdominal pain, thrombocytopenia, nausea, dizziness, paresthesia, depression, cholelithiasis, cholecystitis, fatigue, chest pain, chest discomfort, edema, weakness, generalized edema, headache, diabetic neuropathy, tremors, epigastric pain, vomiting, gastritis, dry mouth, epigastric discomfort, belching, gastrointestinal disorders, gastroesophageal reflux disease, tongue disorders, palpitations, congestive heart failure, myocardial ischemia, vasculitis, thrombocytopenia, anemia, hypoglycemia, elevated serum creatinine, elevated blood pressure, increased blood urea, increased serum creatine phosphokinase, abnormal liver function tests, worsening heart failure, pulmonary edema, myocardial infarction, arrhythmia, chest pain, blood pressure drop, sinoatrial block, atrioventricular block, abdominal discomfort, precordial pain, diarrhea, loose stools, constipation, skin erythema, maculopapular rash, heaviness, heat sensation, impaired glucose tolerance, weakness, vascular edema, vasculitis, hepatitis, renal failure, myalgia, myopathy, rhabdomyolysis, immune-mediated myopathy, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, severe muscle weakness, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a sealed container. Also, avoid extreme temperatures and store at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP × 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.